Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:TORC

resTORbio (TORC) Stock Price, News & Analysis

→ 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad)
Free TORC Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.58
▼
$1.68
50-Day Range
$2.28
▼
$14.77
52-Week Range
$0.86
▼
$10.50
Volume
1.06 million shs
Average Volume
1.15 million shs
Market Capitalization
$58.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
TORC stock logo

About resTORbio Stock (NASDAQ:TORC)

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

TORC Stock News Headlines

January 30, 2024 | investing.com
Adicet Bio Inc (ACET)
February 24, 2023 | finance.yahoo.com
Michelle Chaka Joins Torc as Senior Vice President, Safety and Regulatory
January 10, 2023 | finance.yahoo.com
TinOne Resources Inc. (TORC.V)
September 19, 2022 | forbes.com
Celebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbes
September 12, 2022 | bizjournals.com
Fast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business Journals
July 8, 2022 | streetinsider.com
Form DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.com
June 21, 2022 | gurufocus.com
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.com
June 1, 2022 | streetinsider.com
Terns Pharmaceuticals Inc. (TERN) Appoints Kerry Russell as Chief Medical Officer - StreetInsider.com
June 1, 2022 | streetinsider.com
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - StreetInsider.com
June 1, 2022 | globenewswire.com
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GlobeNewswire
April 27, 2022 | streetinsider.com
PureTech Announces Annual Results for Year Ended December 31, 2021 - StreetInsider.com
April 26, 2022 | businesswire.com
PureTech Announces Annual Results for Year Ended December 31, 2021 - Business Wire
March 21, 2022 | businesswire.com
$3.68 Billion Worldwide Cellular Immunotherapy Industry to 2031 - Identify Growth Segments for Investment - ResearchAndMarkets.com - Business Wire
March 15, 2022 | marketscreener.com
ADICET BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.com
February 8, 2022 | seekingalpha.com
Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate - Seeking Alpha
January 3, 2022 | forbes.com
Can The Pharmaceutical Companies Use Basic Aging Biology To Develop Drugs For Age-Related Diseases? - Forbes
December 9, 2021 | bizjournals.com
Adicet soars on early clinical data for cancer cell therapy - San Francisco Business Times - San Francisco Business Times
November 11, 2021 | marketscreener.com
ADICET BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - marketscreener.com
October 30, 2021 | marketscreener.com
ADICET BIO, INC. : Termination of a Material Definitive Agreement (form 8-K) - marketscreener.com
October 20, 2021 | nasdaq.com
Nasdaq’s ConnectIR Surpasses 10,000 Bookings as Activity Surges Amid Pandemic - Nasdaq
August 12, 2021 | prnewswire.com
Global Cellular Immunotherapy Market research Report 2021: Companies are Focusing on Developing Off-the-Shelf Allogeneic Therapies for New and Improved Cancer Treatment - PRNewswire
August 3, 2021 | streetinsider.com
Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors - StreetInsider.com
August 3, 2021 | streetinsider.com
Oyster Point Pharma Inc. (OYST) Appoints Donald Santel to its Board - StreetInsider.com
August 2, 2021 | finance.yahoo.com
Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors - Yahoo Finance
See More Headlines

Company Calendar

Last Earnings
7/30/2020
Today
5/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TORC
CUSIP
N/A
CIK
1720580
Web
www.restorbio.com
Phone
(857) 315-5521
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-82,740,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-78.12%
Return on Assets
-71.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
20.69
Quick Ratio
20.69

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.24 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
36,454,000
Free Float
N/A
Market Cap
$58.33 million
Optionable
Not Optionable
Beta
2.43

Key Executives

  • Chen Schor
    President, CEO, Secretary & Director
  • Stewart Abbot
    SVP, Chief Operating & Scientific Officer
  • Nick Harvey
    Chief Financial Officer
  • Francesco Galimi
    Chief Medical Officer & Senior Vice President
  • Donald Healey
    Chief Technology Officer

Key Competitors

View All Competitors

TORC Stock Analysis - Frequently Asked Questions

How were resTORbio's earnings last quarter?

resTORbio, Inc. (NASDAQ:TORC) posted its earnings results on Thursday, July, 30th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07.

What other stocks do shareholders of resTORbio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other resTORbio investors own include SCYNEXIS (SCYX), Novavax (NVAX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), Spectrum Pharmaceuticals (SPPI), Viking Therapeutics (VKTX) and CymaBay Therapeutics (CBAY).

When did resTORbio IPO?

resTORbio (TORC) raised $86 million in an initial public offering on Friday, January 26th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

This page (NASDAQ:TORC) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Next President (Not Trump. Not Biden.)
The Freeport Society
Urgent Nvidia Warning
Altimetry
Elon’s New Device is About to Shock the World
InvestorPlace
"The Biggest Drug Ever" Is Coming
Behind the Markets
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders